feed,title,long_url,short_url
Benzinga,Aurinia Pharma's Stock Gains After Lupkynis Data From Late-Stage Lupus Nephritis Study Published In Lancet,https://benzinga.com/general/biotech/21/05/21029590/aurinia-pharmas-stock-gains-after-lupkynis-data-from-late-stage-lupus-nephritis-study-published-i,https://j.mp/3ezmANv
